Key Takeaways
- Domestic business still trailing, but base stabilizes: India branded business grew just 5% YoY as GST 2.0 billing disruptions and a high acute-care base compressed the quarter; management expects the represented market to catch up with IPM growth soon.
- US generics volume engine compensates for price erosion: US business grew 21% on new launches including generic Entresto and ramp-up of existing products, even as Entresto pricing came in lower than expected and competitive intensity remains high.
- Branded US entry via Pivya is a deliberate margin trade-off: The Utility Therapeutics acquisition marks entry into the US branded market with a UTI product launching late Q4; near-term profitability will take a hit from field force investment before revenue ramps on a J-curve.
- R&D spend jumps 41% but full-year guidance holds: Quarterly R&D hit ₹187 crores on peptide development and injectable filing activity; management insists the ₹600-650 crore annual envelope is intact and R&D will not return to the 12-14% of revenue era.
- What to watch next quarter: Whether the GST-disrupted India demand recovers in October data, the pace of Entresto erosion against new launch ramp-ups, and any visibility on complex injectable approvals that could lift plant utilization.
India Branded Business: Stabilization, Not Acceleration
- GST 2.0 compressed the billing cycle: Implementation to pass lower GST rates to end users caused a billing pause for a few days in September, with the East Zone additionally hit by festive season shifts from October to September.
- Acute-care base effect is fading: The represented market for Alembic's acute portfolio has underperformed overall IPM growth for several years post-COVID; management says that base is now stabilizing and represented market growth should catch up with market growth soon.
- Portfolio bright spots: Gynecology, ophthalmology and animal health continued to outperform; Azithral base is stabilizing and beginning to show upward movement.
- H2 base effect looms: Last year's second half carried a higher base, so while growth continues, the comparison gets tougher. Full impact of improved field force productivity is expected only from next financial year.
G. Krishnan: "I would like to, actually, you know, if you look at the, from purely from a modeling perspective, if you look at the growth for the second half of the financial year, you should consider the fact that the last year's second half was a higher base."
US Generics: Volume Offsets Price, But Entresto Disappoints
- Volume-driven growth despite pricing headwinds: The 21% US growth came from new launches (Entresto plus 3-4 others) and gradual ramp-up in existing supply products, with no one-off shortage opportunities.
- Entresto pricing undershot expectations: Competition was intense and pricing came in lower than management had hoped; some erosion has already occurred since launch. The company gained meaningful accounts with decent share, but the product will not be the margin tailwind initially anticipated.
- Sustainability hinges on launch cadence: Management believes the current Q2 revenue level is sustainable unless larger launches like Entresto see further erosion; 4-5 new products are expected in Q3 and another 4-5 in Q4.
- Gross margin outlook steady: US gross margins softened QoQ on product mix, but management expects year-end gross margins in the 70-75% range.
Pranav Amin: "That's been picked up. Well, there was a lot of competition on that product, and pricing was much lower than what I would have liked or would have expected."
Pivya & the Branded US Pivot
- The acquisition: Alembic acquired Utility Therapeutics, gaining Pivya, a product for urinary tract infections with marketing exclusivity in the US. The deal structure includes an upfront payment of ~$4 million, milestone payments of $4 million each linked to US launch and revenue milestones, plus profit sharing with sellers.
- The clinical positioning: Pivya is a tried-and-tested product commercialized in Europe for many years; it works well in pregnant women and offers a safe alternative in a therapy area that has seen little product introduction for more than a decade.
- Launch timeline and ramp: Launch is expected to start late Q4 FY26, with Q1 FY27 as the first full quarter. Revenue will ramp on a J-curve or umbrella curve, taking at least a couple of quarters to gain traction.
- Investment and near-term margin drag: The company will build a field force starting with high-prescribing doctors in women's health, expanding gradually as sales generate. This will pressure profitability for a couple of quarters.
- Strategic intent: Management views this as a de-risk from generic pricing challenges and aims to build a women's health franchise, actively scouting for in-licensing and additional products in the space.
Pranav Amin: "I believe this can be a good de-risk from the generic business and the pricing challenges that we have in the generic business. And we can build a good franchise in women's health. And that's something that we're going to aim to do."
R&D and Pipeline: Peptides and Complex Injectables
- Spend spike explained: R&D rose 41% YoY to ₹187 crores, driven by formulation development in injectables and complex injectables, plus a new peptide lab. Tirzepatide (Mounjaro) batches were executed during the quarter, causing a cost bump.
- Full-year guidance intact: Despite the quarterly spike, management reaffirmed the ₹600-650 crore annual R&D guidance, with full-year spend expected at ~8% of revenue.
- Peptide ambitions: A peptide lab has been set up; GLP-1 products including semaglutide and tirzepatide are under development. One peptide has already been approved, though GLP-1 approvals still have time. The company believes it will be in the first phase of tirzepatide launches in many markets, though not for semaglutide in Canada or the US.
- Complex injectable catalysts: Some approvals are expected in the next couple of months; these are described as more meaningful with limited competition. Utilization of the injectable and oncology plants should improve once product approvals start coming through, with back-ended launches expected in H2 itself.
Pranav Amin: "To be honest, I don't think we will ever go back to the 12%-13%-14% kind of R&D spends that we were doing when margins and the returns in the US are much higher than what they are right now."
International Generics and API
- ROW generics exceptional quarter, not a new run-rate: The 30% growth in rest-of-world markets was amplified by a low base in H1 last year due to supply difficulties; H2 last year had a much higher base. Full-year growth is expected at 15-20%.
- API remains challenging: The 15% growth this quarter came off a lower base and included some development quantities; the API business has been sluggish for eight quarters and the outlook remains cautious.
Margins, Debt and the Path to 20% EBITDA
- Working capital and debt rose on operating intensity: Net working capital increased to ₹2,921 crores and net debt to ₹1,280 crores, reflecting new launches, new facilities, and the Pivya acquisition. Interest costs rose to ₹76 crores.
- Debt reduction expected gradually: Excluding Pivya launch investment, net debt levels are expected to reduce gradually in FY27, contingent on successful new product launches and growth from new facilities.
- Margin expansion thesis: Management expects EBITDA margins to improve to 18-19% over the next couple of years and reach 20% thereafter. Drivers include India business returning to growth, animal health and gynecology outperformance, US growth, and increasing utilization of injectable and oncology facilities.
- Operating leverage from fixed costs: Other expenses are predominantly fixed and grew below revenue, providing operating leverage as capacity utilization improves across the business, subject to price impact.
- Near-term normalization: Margins are expected to start normalizing from Q3 and Q4 onwards.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| R&D spend | ₹600-650 crores full-year (~8% of revenue) | FY26 |
| US product launches | 4-5 products in Q3, 4-5 in Q4 | FY26 |
| Pivya US launch | Begin late Q4; Q1 FY27 first full quarter | Late Q4 FY26 |
| ROW generics growth | 15-20% full-year (vs 30% in Q2) | FY26 |
| EBITDA margin | Improve to 18-19%, then 20% | Next couple of years |
| Net debt reduction | Gradual reduction ex-Pivya investment | FY27 |
| India business catch-up | Represented market growth to match IPM growth | Soon (no date) |
| Complex injectable approvals | Some approvals expected; limited competition | Next couple of months |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue (half-yearly) | ₹3,621 cr, +13% YoY |
| India Branded Business revenue | ₹639 cr, +5% YoY |
| US business growth | +21%, supported by higher volumes |
| Rest of world markets growth | +31%, exceptional due to low base in H1 last year |
| API business growth | +15% |
| EBITDA before R&D (half-yearly) | ₹927 cr, margin 26%, +28% YoY |
| EBITDA post R&D (half-yearly) | ₹613 cr, ~17% of revenue |
| R&D expenses | ₹187 cr, +41% YoY; ~10% of revenue |
| Profit before tax (before exceptional items) | ₹225 cr, +34% YoY |
| Profit after tax (before exceptional items) | ₹185 cr, +30% YoY |
| Profit after tax adjusted for insurance claim | +20% YoY |
| Net debt | ₹1,280 cr as of 30 Sep, vs ₹967 cr in Jun '25 |
| Net working capital | ₹2,921 cr vs ₹2,734 cr as of Mar '25 |
| Interest cost | ₹76 cr, up from ₹71 cr in Q1 |
| ANDAs filed during quarter | 2, cumulative filings at 269 |
| ANDA approvals received | 6 approvals and 1 tentative approval |
| Products launched in US | 3 |
| Cumulative ANDA approvals | 226 including 21 tentative approvals |
| Expected US launches | 4-5 in Q3 and 4-5 in Q4 FY26 |
| Full-year R&D guidance | ₹600-650 cr, maintained |
| ROW generics expected full-year growth | 15-20% |
| API expected full-year growth | ~10% |
| US gross margin guidance | 70-75% range reiterated |
| R&D spend going forward | ~8% of revenue |